Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli Zuckerman

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Antiviral Therapy|January 10, 2017
HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patientsYael Gozlan, Ziv Ben-Ari, Roy Moscona, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|April 8, 2023
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countriesHomie A Razavi, Maria Buti, Norah A Terrault, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Antiviral Therapy|January 10, 2017
HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patientsYael Gozlan, Ziv Ben-Ari, Roy Moscona, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|April 8, 2023
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countriesHomie A Razavi, Maria Buti, Norah A Terrault, et al.
Pageof 4